Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2012

Open Access 01-12-2012 | Technical advance

Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer

Authors: Isabelle Soerjomataram, Joannie Lortet-Tieulent, Jacques Ferlay, David Forman, Colin Mathers, D Maxwell Parkin, Freddie Bray

Published in: BMC Medical Research Methodology | Issue 1/2012

Login to get access

Abstract

Background

Disability-adjusted life years (DALYs) link data on disease occurrence to health outcomes, and they are a useful aid in establishing country-specific agendas regarding cancer control. The variables required to compute DALYs are however multiple and not readily available in many countries. We propose a methodology that derives global DALYs and validate variables and DALYs based on data from various cancer registries.

Methods

We estimated DALYs for four countries (Norway, Bulgaria, India and Uganda) within each category of the human development index (HDI). The following sources (indicators) were used: Globocan2008 (incidence and mortality), various cancer registries (proportion cured, proportion treated and duration of disease), treatment guidelines (duration of treatment), specific burden of disease studies (sequelae and disability weights), alongside expert opinion. We obtained country-specific population estimates and identified resource levels using the HDI, DALYs are computed as the sum of years of life lost and years lived with disabilities.

Results

Using mortality:incidence ratios to estimate country-specific survival, and by applying the human development index we derived country-specific estimates of the proportion cured and the proportion treated. The fit between the estimates and observed data from the cancer registries was relatively good. The final DALY estimates were similar to those computed using observed values in Norway, and in WHO’s earlier global burden of disease study. Marked cross-country differences in the patterns of DALYs by cancer sites were observed. In Norway and Bulgaria, breast, colorectal, prostate and lung cancer were the main contributors to DALYs, representing 54% and 45%, respectively, of the totals. These cancers contributed only 27% and 18%, respectively, of total DALYs in India and Uganda.

Conclusions

Our approach resulted in a series of variables that can be used to estimate country-specific DALYs, enabling global estimates of DALYs and international comparisons that support priorities in cancer control.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization: The global burden of disease: 2004 update. 2008, Geneva: World Health Organization World Health Organization: The global burden of disease: 2004 update. 2008, Geneva: World Health Organization
2.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed
3.
go back to reference Murray CLM, Lopez AD: The Global Burden of Disease. 1996, Boston: Harvard School of Public Health Murray CLM, Lopez AD: The Global Burden of Disease. 1996, Boston: Harvard School of Public Health
4.
go back to reference Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M, group EW: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007, 8 (9): 773-783. 10.1016/S1470-2045(07)70245-0.CrossRefPubMed Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M, group EW: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007, 8 (9): 773-783. 10.1016/S1470-2045(07)70245-0.CrossRefPubMed
5.
go back to reference Victorian burden of disease study: Mortality and morbidity in 2001. 2005, Melbourne: The Public Health Group, Rural and Regional Health and Aged Care Services Division. Victorian Government Department of Human Services Victorian burden of disease study: Mortality and morbidity in 2001. 2005, Melbourne: The Public Health Group, Rural and Regional Health and Aged Care Services Division. Victorian Government Department of Human Services
6.
go back to reference Stouthard M, Essink-Bot ML, Bonsel G, Barendregt J, Kramers PG: Disability weights for diseases in the Netherlands. 1997, Rotterdam: Department of Public Health, Erasmus University Stouthard M, Essink-Bot ML, Bonsel G, Barendregt J, Kramers PG: Disability weights for diseases in the Netherlands. 1997, Rotterdam: Department of Public Health, Erasmus University
7.
go back to reference Murray CJ: Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994, 72 (3): 429-445.PubMedPubMedCentral Murray CJ: Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994, 72 (3): 429-445.PubMedPubMedCentral
8.
go back to reference Doll R, Payne P, Waterhouse JAH: Cancer incidence in five continents, vol. 1. 1966, Geneva: Union Internationale Contre le CancerCrossRef Doll R, Payne P, Waterhouse JAH: Cancer incidence in five continents, vol. 1. 1966, Geneva: Union Internationale Contre le CancerCrossRef
9.
go back to reference Lambert PC, Thompson JR, Weston CL, Dickman PW: Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007, 8 (3): 576-594.CrossRefPubMed Lambert PC, Thompson JR, Weston CL, Dickman PW: Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007, 8 (3): 576-594.CrossRefPubMed
10.
go back to reference Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999, 83 (1): 18-29.CrossRefPubMed Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999, 83 (1): 18-29.CrossRefPubMed
11.
go back to reference Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, Visser O, Verbeek AL, Kiemeney LA: The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011, 21 (5): 573-577. 10.1093/eurpub/ckq120.CrossRefPubMed Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, Visser O, Verbeek AL, Kiemeney LA: The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011, 21 (5): 573-577. 10.1093/eurpub/ckq120.CrossRefPubMed
12.
go back to reference United Nations Development Programme: Human Development Reports 2011: Sustainability and equitability. A better future for all. 2011, New York: United Nations Development Programme United Nations Development Programme: Human Development Reports 2011: Sustainability and equitability. A better future for all. 2011, New York: United Nations Development Programme
13.
go back to reference Småstuen M, Aagnes B, Johannesen TB, Møller B, Bray F: Long-term cancer survival: patterns and trends in Norway 1965–2007. 2008, Oslo: Cancer Registry of Norway Småstuen M, Aagnes B, Johannesen TB, Møller B, Bray F: Long-term cancer survival: patterns and trends in Norway 1965–2007. 2008, Oslo: Cancer Registry of Norway
14.
go back to reference de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, Coebergh JW: Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008, 19 (3): 583-589.CrossRefPubMed de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, Coebergh JW: Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008, 19 (3): 583-589.CrossRefPubMed
15.
go back to reference Kvale R, Moller B, Angelsen A, Dahl O, Fossa SD, Halvorsen OJ, Hoem L, Solberg A, Wahlqvist R, Bray F: Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiol. 2010, 34 (4): 359-367. 10.1016/j.canep.2010.04.017.CrossRefPubMed Kvale R, Moller B, Angelsen A, Dahl O, Fossa SD, Halvorsen OJ, Hoem L, Solberg A, Wahlqvist R, Bray F: Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiol. 2010, 34 (4): 359-367. 10.1016/j.canep.2010.04.017.CrossRefPubMed
16.
go back to reference Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G, Scandinavian Prostate Cancer Group Study N: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009, 55 (2): 422-430. 10.1016/j.eururo.2008.08.054.CrossRefPubMed Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G, Scandinavian Prostate Cancer Group Study N: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009, 55 (2): 422-430. 10.1016/j.eururo.2008.08.054.CrossRefPubMed
17.
go back to reference Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O: Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005, 97 (21): 1580-1588. 10.1093/jnci/dji339.CrossRefPubMed Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O: Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005, 97 (21): 1580-1588. 10.1093/jnci/dji339.CrossRefPubMed
18.
go back to reference Fossa SD, Ous S, Espetveit S, Langmark F: Patterns of primary care and survival in 336 consecutive unselected Norwegian patients with bladder cancer. Scand J Urol Nephrol. 1992, 26 (2): 131-138.CrossRefPubMed Fossa SD, Ous S, Espetveit S, Langmark F: Patterns of primary care and survival in 336 consecutive unselected Norwegian patients with bladder cancer. Scand J Urol Nephrol. 1992, 26 (2): 131-138.CrossRefPubMed
19.
go back to reference Hardt J, Filipas D, Hohenfellner R, Egle UT: Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study. Qual Life Res. 2000, 9 (1): 1-12. 10.1023/A:1008927809013.CrossRefPubMed Hardt J, Filipas D, Hohenfellner R, Egle UT: Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study. Qual Life Res. 2000, 9 (1): 1-12. 10.1023/A:1008927809013.CrossRefPubMed
20.
go back to reference Organisation for Economic Co-operation and Development: OECD Health Data 2010. 2010, Paris: Organisation for Economic Co-operation and Development Organisation for Economic Co-operation and Development: OECD Health Data 2010. 2010, Paris: Organisation for Economic Co-operation and Development
22.
go back to reference Morris E, Quirke P, Thomas JD, Fairley L, Cottier B, Forman D: Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene?. Gut. 2008, 57 (12): 1690-1697. 10.1136/gut.2007.137877.CrossRefPubMed Morris E, Quirke P, Thomas JD, Fairley L, Cottier B, Forman D: Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene?. Gut. 2008, 57 (12): 1690-1697. 10.1136/gut.2007.137877.CrossRefPubMed
23.
go back to reference Allemani C, Storm H, Voogd AC, Holli K, Izarzugaza I, Torrella-Ramos A, Bielska-Lasota M, Aareleid T, Ardanaz E, Colonna M, et al: Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study. Eur J Cancer. 2010, 46 (9): 1528-1536. 10.1016/j.ejca.2010.02.016.CrossRefPubMed Allemani C, Storm H, Voogd AC, Holli K, Izarzugaza I, Torrella-Ramos A, Bielska-Lasota M, Aareleid T, Ardanaz E, Colonna M, et al: Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study. Eur J Cancer. 2010, 46 (9): 1528-1536. 10.1016/j.ejca.2010.02.016.CrossRefPubMed
24.
go back to reference Cancer Registry of Norway. Cancer in Norway 2008: Cancer incidence, mortality, survival and prevalence in Norway. 2009, Oslo: Cancer Registry of Norway Cancer Registry of Norway. Cancer in Norway 2008: Cancer incidence, mortality, survival and prevalence in Norway. 2009, Oslo: Cancer Registry of Norway
25.
go back to reference Bray F, Engholm G, Hakulinen T, Gislum M, Tryggvadottir L, Storm HH, Klint A: Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol. 2010, 49 (5): 673-693. 10.3109/02841861003610200.CrossRefPubMed Bray F, Engholm G, Hakulinen T, Gislum M, Tryggvadottir L, Storm HH, Klint A: Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol. 2010, 49 (5): 673-693. 10.3109/02841861003610200.CrossRefPubMed
26.
go back to reference Bray F, Klint A, Gislum M, Hakulinen T, Engholm G, Tryggvadottir L, Storm HH: Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol. 2010, 49 (5): 644-654. 10.3109/02841860903575315.CrossRefPubMed Bray F, Klint A, Gislum M, Hakulinen T, Engholm G, Tryggvadottir L, Storm HH: Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol. 2010, 49 (5): 644-654. 10.3109/02841860903575315.CrossRefPubMed
27.
go back to reference Engholm G, Hakulinen T, Gislum M, Tryggvadottir L, Klint A, Bray F, Storm HH: Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2006, 49 (5): 655-664.CrossRef Engholm G, Hakulinen T, Gislum M, Tryggvadottir L, Klint A, Bray F, Storm HH: Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2006, 49 (5): 655-664.CrossRef
28.
go back to reference Hakulinen T, Engholm G, Gislum M, Storm HH, Klint A, Tryggvadottir L, Bray F: Trends in the survival of patients diagnosed with cancers in the respiratory system in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2006, 49 (5): 608-623.CrossRef Hakulinen T, Engholm G, Gislum M, Storm HH, Klint A, Tryggvadottir L, Bray F: Trends in the survival of patients diagnosed with cancers in the respiratory system in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2006, 49 (5): 608-623.CrossRef
29.
go back to reference Hakulinen T, Tryggvadottir L, Gislum M, Storm HH, Bray F, Klint A, Engholm G: Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010, 49 (5): 561-577. 10.3109/02841860903575307.CrossRefPubMed Hakulinen T, Tryggvadottir L, Gislum M, Storm HH, Bray F, Klint A, Engholm G: Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010, 49 (5): 561-577. 10.3109/02841860903575307.CrossRefPubMed
30.
go back to reference Rayson D, Saint-Jacques N, Younis T, Meadows J, Dewar R: Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04. CMAJ. 2007, 176 (3): 327-332. 10.1503/cmaj.060825.CrossRefPubMedPubMedCentral Rayson D, Saint-Jacques N, Younis T, Meadows J, Dewar R: Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04. CMAJ. 2007, 176 (3): 327-332. 10.1503/cmaj.060825.CrossRefPubMedPubMedCentral
31.
go back to reference van Steenbergen LN, Lemmens VE, Rutten HJ, Martijn H, Coebergh JW: Was there shortening of the interval between diagnosis and treatment of colorectal cancer in southern Netherlands between 2005 and 2008?. World J Surg. 2010, 34 (5): 1071-1079. 10.1007/s00268-010-0480-x.CrossRefPubMedPubMedCentral van Steenbergen LN, Lemmens VE, Rutten HJ, Martijn H, Coebergh JW: Was there shortening of the interval between diagnosis and treatment of colorectal cancer in southern Netherlands between 2005 and 2008?. World J Surg. 2010, 34 (5): 1071-1079. 10.1007/s00268-010-0480-x.CrossRefPubMedPubMedCentral
32.
go back to reference Anand S, Hanson K: Disability-adjusted life years: a critical review. J Health Econ. 1997, 16 (6): 685-702. 10.1016/S0167-6296(97)00005-2.CrossRefPubMed Anand S, Hanson K: Disability-adjusted life years: a critical review. J Health Econ. 1997, 16 (6): 685-702. 10.1016/S0167-6296(97)00005-2.CrossRefPubMed
33.
go back to reference Sankaranarayanan R, Boffetta P: Research on cancer prevention, detection and management in low- and medium-income countries. Ann Oncol. 2010, 21 (10): 1935-1943. 10.1093/annonc/mdq049.CrossRefPubMed Sankaranarayanan R, Boffetta P: Research on cancer prevention, detection and management in low- and medium-income countries. Ann Oncol. 2010, 21 (10): 1935-1943. 10.1093/annonc/mdq049.CrossRefPubMed
34.
go back to reference Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, et al: Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010, 376 (9747): 1186-1193. 10.1016/S0140-6736(10)61152-X.CrossRefPubMed Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, et al: Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010, 376 (9747): 1186-1193. 10.1016/S0140-6736(10)61152-X.CrossRefPubMed
35.
go back to reference Bray FI, Weiderpass E: Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007. Int J Cancer. 2010, 126 (6): 1454-1466.PubMed Bray FI, Weiderpass E: Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007. Int J Cancer. 2010, 126 (6): 1454-1466.PubMed
36.
go back to reference Alvarez-Martin E, Morant-Ginestar C, Genova-Maleras R, Gil A, Perez-Gomez B, Lopez-Abente G, Fernandez de Larrea-Baz N: Burden of disease due to cancer in Spain. BMC Publ Health. 2009, 42: 9-42. Alvarez-Martin E, Morant-Ginestar C, Genova-Maleras R, Gil A, Perez-Gomez B, Lopez-Abente G, Fernandez de Larrea-Baz N: Burden of disease due to cancer in Spain. BMC Publ Health. 2009, 42: 9-42.
37.
go back to reference Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli MT, Ebrahim S, Ezzati M, Salomon JA, Kreiser JG, et al: The burden of disease and injury in the United States 1996. Popul Health Metr. 2006, 4: 11-10.1186/1478-7954-4-11.CrossRefPubMedPubMedCentral Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli MT, Ebrahim S, Ezzati M, Salomon JA, Kreiser JG, et al: The burden of disease and injury in the United States 1996. Popul Health Metr. 2006, 4: 11-10.1186/1478-7954-4-11.CrossRefPubMedPubMedCentral
38.
go back to reference Jankovic S, Vlajinac H, Bjegovic V, Marinkovic J, Sipetic-Grujicic S, Markovic-Denic L, Kocev N, Santric-Milicevic M, Terzic-Supic Z, Maksimovic N, et al: The burden of disease and injury in Serbia. Eur J Public Health. 2007, 17 (1): 80-85.CrossRefPubMed Jankovic S, Vlajinac H, Bjegovic V, Marinkovic J, Sipetic-Grujicic S, Markovic-Denic L, Kocev N, Santric-Milicevic M, Terzic-Supic Z, Maksimovic N, et al: The burden of disease and injury in Serbia. Eur J Public Health. 2007, 17 (1): 80-85.CrossRefPubMed
39.
go back to reference Murthy NS, Nandakumar BS, Pruthvish S, George PS, Mathew A: Disability adjusted life years for cancer patients in India. Asian Pac J Cancer Prev. 2010, 11 (3): 633-640.PubMed Murthy NS, Nandakumar BS, Pruthvish S, George PS, Mathew A: Disability adjusted life years for cancer patients in India. Asian Pac J Cancer Prev. 2010, 11 (3): 633-640.PubMed
40.
go back to reference Phua HP, Chua AV, Ma S, Heng D, Chew SK: Singapore's burden of disease and injury 2004. Singapore Med J. 2009, 50 (5): 468-478.PubMed Phua HP, Chua AV, Ma S, Heng D, Chew SK: Singapore's burden of disease and injury 2004. Singapore Med J. 2009, 50 (5): 468-478.PubMed
41.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
42.
go back to reference Pineros M, Sanchez R, Perry F, Garcia OA, Ocampo R, Cendales R: Delay for diagnosis and treatment of breast cancer in Bogota, Colombia. Salud Publica Mex. 2011, 53 (6): 478-485.PubMed Pineros M, Sanchez R, Perry F, Garcia OA, Ocampo R, Cendales R: Delay for diagnosis and treatment of breast cancer in Bogota, Colombia. Salud Publica Mex. 2011, 53 (6): 478-485.PubMed
43.
go back to reference Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW: Cancer care challenges in developing countries. Cancer. 2011 Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW: Cancer care challenges in developing countries. Cancer. 2011
44.
go back to reference Sulu E, Tasolar O, Berk Takir H, Yagci Tuncer L, Karakurt Z, Yilmaz A: Delays in the diagnosis and treatment of non-small-cell lung cancer. Tumori. 2011, 6: 693-697. Sulu E, Tasolar O, Berk Takir H, Yagci Tuncer L, Karakurt Z, Yilmaz A: Delays in the diagnosis and treatment of non-small-cell lung cancer. Tumori. 2011, 6: 693-697.
45.
go back to reference Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N: Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010, 11 (5): 490-498. 10.1016/S1470-2045(09)70317-1.CrossRefPubMed Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N: Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010, 11 (5): 490-498. 10.1016/S1470-2045(09)70317-1.CrossRefPubMed
46.
go back to reference Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, Coebergh JW, Nijsten T: Impact of melanoma on patients' lives among 562 survivors: a dutch population-based study. Arch Dermatol. 2011, 147 (2): 177-185. 10.1001/archdermatol.2010.433.CrossRefPubMed Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, Coebergh JW, Nijsten T: Impact of melanoma on patients' lives among 562 survivors: a dutch population-based study. Arch Dermatol. 2011, 147 (2): 177-185. 10.1001/archdermatol.2010.433.CrossRefPubMed
Metadata
Title
Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer
Authors
Isabelle Soerjomataram
Joannie Lortet-Tieulent
Jacques Ferlay
David Forman
Colin Mathers
D Maxwell Parkin
Freddie Bray
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2012
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-12-125

Other articles of this Issue 1/2012

BMC Medical Research Methodology 1/2012 Go to the issue